Compare REX AI Equity Premium Income ETF (AIPI) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs CVS Health Corp — how do they compare? REX AI Equity Premium Income ETF trades at $36.27, while CVS Health Corp trades at $104.36 (market cap $133.12B). The key difference: CVS Health Corp pays a 2.55% dividend while REX AI Equity Premium Income ETF pays none, and CVS Health Corp is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | CVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $104.81 |
52-Week Low | $32.45 | $58.75 |
Market Cap | — | $133.12B |
Enterprise Value | — | $199.66B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
CVS Health trades at $104.33, down slightly on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, including a recent Q1 2026 beat, and benefits from positive sentiment around strategic initiatives like GLP-1 drug access. Revenue growth remains solid, though net margins are thin. The current price sits just below the consensus price target of $106.86.
The outlook for CVS is positive, driven by earnings momentum and strategic positioning in healthcare services. Key opportunities include margin expansion potential and market share gains. Risks involve intense competition, regulatory pressures on healthcare pricing, and the company's significant debt load, which requires careful management of cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
